{"product_id":"ghrp-2-5mg","title":"GHRP-2 5mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"641\" data-start=\"54\"\u003e\u003cstrong\u003eGHRP-2 \u003c\/strong\u003eis a synthetic \u003cstrong data-end=\"159\" data-start=\"109\"\u003ehexapeptide ghrelin-receptor (GHSR-1a) agonist\u003c\/strong\u003e that provokes \u003cstrong data-end=\"222\" data-start=\"174\"\u003erapid, pulsatile growth-hormone (GH) release\u003c\/strong\u003e and modest rises in \u003cstrong data-end=\"275\" data-start=\"243\"\u003eprolactin, ACTH and cortisol\u003c\/strong\u003e. Unlike GHRH analogs, it \u003cstrong data-end=\"356\" data-start=\"301\"\u003eacts directly on pituitary and hypothalamic GHSR-1a\u003c\/strong\u003e via phospholipase-C\/IP₃-Ca²⁺ signalling. Pralmorelin is \u003cstrong data-end=\"480\" data-start=\"413\"\u003eapproved in Japan as a diagnostic agent for adult GH deficiency\u003c\/strong\u003e (intravenous bolus 0.5 µg kg⁻¹); elsewhere it is supplied through research\/pharmacy-compounding channels for off-label endocrino-metabolic or “anti-aging” uses.\u003c\/p\u003e\n\u003chr data-end=\"646\" data-start=\"643\"\u003e\n\u003ch3 data-end=\"705\" data-start=\"648\"\u003eAdditional Benefits of GHRP-2 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2883\" data-start=\"707\"\u003e\n\u003cthead data-end=\"735\" data-start=\"707\"\u003e\n\u003ctr data-end=\"735\" data-start=\"707\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"717\" data-start=\"707\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"735\" data-start=\"717\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2883\" data-start=\"746\"\u003e\n\u003ctr data-end=\"1026\" data-start=\"746\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"793\" data-start=\"746\"\u003e\u003cstrong data-end=\"792\" data-start=\"748\"\u003e1 Physiologic GH pulsatility restoration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1026\" data-start=\"793\"\u003eNightly SC or intranasal GHRP-2 \u003cstrong data-end=\"872\" data-start=\"827\"\u003enormalises age-blunted nocturnal GH peaks\u003c\/strong\u003e without sustained IGF-1 over-elevation, preserving feedback integrity. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1279\" data-start=\"1027\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1070\" data-start=\"1027\"\u003e\u003cstrong data-end=\"1069\" data-start=\"1029\"\u003e2 Appetite \u0026amp; weight gain in cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1279\" data-start=\"1070\"\u003eAs a ghrelin mimetic, GHRP-2 \u003cstrong data-end=\"1140\" data-start=\"1101\"\u003eincreases hunger and caloric intake\u003c\/strong\u003e; short trials in cancer\/cachectic COPD show \u003cstrong data-end=\"1210\" data-start=\"1185\"\u003e2–3 kg lean-mass gain\u003c\/strong\u003e in 4–6 weeks. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Nutrition; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1540\" data-start=\"1280\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1313\" data-start=\"1280\"\u003e\u003cstrong data-end=\"1312\" data-start=\"1282\"\u003e3 Muscle protein synthesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1540\" data-start=\"1313\"\u003eRodent hind-limb unloading plus GHRP-2 preserved \u003cstrong data-end=\"1408\" data-start=\"1364\"\u003esolesus CSA and myofibrillar protein FSR\u003c\/strong\u003e, indicating anti-atrophic potential via GH\/IGF-1 and intrinsic GHSR. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;American Journal of Physiology; Muscle \u0026amp; Nerve\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1750\" data-start=\"1541\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1570\" data-start=\"1541\"\u003e\u003cstrong data-end=\"1569\" data-start=\"1543\"\u003e4 Bone-density support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1750\" data-start=\"1570\"\u003eDaily peptide raised \u003cstrong data-end=\"1614\" data-start=\"1593\"\u003eserum osteocalcin\u003c\/strong\u003e and improved \u003cstrong data-end=\"1642\" data-start=\"1628\"\u003etibial BMD\u003c\/strong\u003e by 6 % in ovariectomised rats—mirroring GH anabolic actions. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Journal of Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1987\" data-start=\"1751\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1790\" data-start=\"1751\"\u003e\u003cstrong data-end=\"1789\" data-start=\"1753\"\u003e5 Sleep-architecture enhancement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1987\" data-start=\"1790\"\u003eBedtime dosing augments \u003cstrong data-end=\"1841\" data-start=\"1816\"\u003eslow-wave sleep (SWS)\u003c\/strong\u003e and \u003cstrong data-end=\"1861\" data-start=\"1846\"\u003eREM density\u003c\/strong\u003e, correlating with GH surges and next-day vigilance in middle-aged volunteers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Psychoneuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2200\" data-start=\"1988\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2030\" data-start=\"1988\"\u003e\u003cstrong data-end=\"2029\" data-start=\"1990\"\u003e6 Gastro-intestinal mucosal healing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2200\" data-start=\"2030\"\u003eGHRP-2 accelerates \u003cstrong data-end=\"2088\" data-start=\"2051\"\u003egastric and colonic ulcer closure\u003c\/strong\u003e via anti-apoptotic and angiogenic effects independent of GH. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Gut; American Journal of Pathology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2442\" data-start=\"2201\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2234\" data-start=\"2201\"\u003e\u003cstrong data-end=\"2233\" data-start=\"2203\"\u003e7 Cardio-protection signal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2442\" data-start=\"2234\"\u003ePre-ischaemic infusion limits \u003cstrong data-end=\"2282\" data-start=\"2266\"\u003einfarct size\u003c\/strong\u003e and preserves ejection fraction in rat I\/R models, linked to \u003cstrong data-end=\"2361\" data-start=\"2344\"\u003ePI3K–Akt–eNOS\u003c\/strong\u003e activation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation Research; Cardiovascular Drugs \u0026amp; Therapy\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2646\" data-start=\"2443\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2469\" data-start=\"2443\"\u003e\u003cstrong data-end=\"2468\" data-start=\"2445\"\u003e8 Immune-modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2646\" data-start=\"2469\"\u003ePeptide attenuates \u003cstrong data-end=\"2516\" data-start=\"2490\"\u003eLPS-induced TNF-α\/IL-6\u003c\/strong\u003e release while sparing anti-viral IFN pathways, suggesting sepsis-adjunct potential. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Shock; Critical Care Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2883\" data-start=\"2647\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2691\" data-start=\"2647\"\u003e\u003cstrong data-end=\"2690\" data-start=\"2649\"\u003e9 Insulin-sensitivity drift (caution)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2883\" data-start=\"2691\"\u003eRepeated dosing can \u003cstrong data-end=\"2751\" data-start=\"2713\"\u003eraise fasting glucose 5–10 mg dL⁻¹\u003c\/strong\u003e via counter-regulatory hormones—monitor glycaemia, especially in pre-diabetes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes Care; Endocrine Connections\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2888\" data-start=\"2885\"\u003e\n\u003ch2 data-end=\"2925\" data-start=\"2890\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2962\" data-start=\"2927\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3196\" data-start=\"2963\"\u003eGHRP-2 binds \u003cstrong data-end=\"2987\" data-start=\"2976\"\u003eGHSR-1a\u003c\/strong\u003e (a GPCR) on hypothalamic neurons and pituitary somatotrophs → \u003cstrong data-end=\"3084\" data-start=\"3050\"\u003eGα\u0026lt;sub\u0026gt;q\/11\u0026lt;\/sub\u0026gt;–PLC–IP₃\/Ca²⁺\u003c\/strong\u003e cascade → GH vesicle exocytosis. It synergises with endogenous GHRH and is partially inhibited by somatostatin.\u003c\/p\u003e\n\u003ch3 data-end=\"3225\" data-start=\"3198\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3569\" data-start=\"3227\"\u003e\n\u003cthead data-end=\"3269\" data-start=\"3227\"\u003e\n\u003ctr data-end=\"3269\" data-start=\"3227\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3237\" data-start=\"3227\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3258\" data-start=\"3237\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3269\" data-start=\"3258\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3569\" data-start=\"3284\"\u003e\n\u003ctr data-end=\"3372\" data-start=\"3284\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3306\" data-start=\"3284\"\u003eGH → GHR–JAK2–STAT5\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3346\" data-start=\"3306\"\u003e↑ IGF-1, lipolysis, protein synthesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3372\" data-start=\"3346\"\u003eLiver, adipose, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3457\" data-start=\"3373\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3388\" data-start=\"3373\"\u003eGhrelin–AMPK\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3431\" data-start=\"3388\"\u003e↑ appetite, gastric motility, GH release\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3457\" data-start=\"3431\"\u003eHypothalamus, GI tract\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3569\" data-start=\"3458\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3492\" data-start=\"3458\"\u003ePI3K–Akt–eNOS (extra-pituitary)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3542\" data-start=\"3492\"\u003eAnti-apoptotic, vasodilatory, cardio-protective\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3569\" data-start=\"3542\"\u003eMyocardium, endothelium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3574\" data-start=\"3571\"\u003e\n\u003ch2 data-end=\"3598\" data-start=\"3576\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"3897\" data-start=\"3600\"\u003e\n\u003cli data-end=\"3698\" data-start=\"3600\"\u003e\n\u003cp data-end=\"3698\" data-start=\"3602\"\u003e\u003cstrong data-end=\"3617\" data-start=\"3602\"\u003eAbsorption:\u003c\/strong\u003e Effective \u003cstrong data-end=\"3662\" data-start=\"3628\"\u003eIV, SC, intranasal, sublingual\u003c\/strong\u003e; oral bioavailability negligible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3805\" data-start=\"3699\"\u003e\n\u003cp data-end=\"3805\" data-start=\"3701\"\u003e\u003cstrong data-end=\"3715\" data-start=\"3701\"\u003eHalf-life:\u003c\/strong\u003e Plasma \u003cstrong data-end=\"3750\" data-start=\"3723\"\u003et\u0026lt;sub\u0026gt;½\u0026lt;\/sub\u0026gt; 20–30 min\u003c\/strong\u003e; GH peak ~30 min post-dose, back to baseline by 2 h.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3897\" data-start=\"3806\"\u003e\n\u003cp data-end=\"3897\" data-start=\"3808\"\u003e\u003cstrong data-end=\"3835\" data-start=\"3808\"\u003eDistribution\/Clearance:\u003c\/strong\u003e Rapid renal\/hepatic peptide degradation; no CYP interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3902\" data-start=\"3899\"\u003e\n\u003ch2 data-end=\"3949\" data-start=\"3904\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"3982\" data-start=\"3951\"\u003e4.1 Cachexia \u0026amp; Sarcopenia\u003c\/h3\u003e\n\u003cp data-end=\"4133\" data-start=\"3983\"\u003ePhase 2 pilot in cancer cachexia showed \u003cstrong data-end=\"4059\" data-start=\"4023\"\u003e↑ caloric intake, lean mass, QOL\u003c\/strong\u003e over 30 days; COPD cohort mirrored gains with functional strength uptick.\u003c\/p\u003e\n\u003ch3 data-end=\"4166\" data-start=\"4135\"\u003e4.2 Endocrine Diagnostics\u003c\/h3\u003e\n\u003cp data-end=\"4311\" data-start=\"4167\"\u003e0.5 µg kg⁻¹ IV bolus provokes \u003cstrong data-end=\"4216\" data-start=\"4197\"\u003e≥3-fold GH rise\u003c\/strong\u003e in healthy adults; blunted response signals pituitary impairment—approved diagnostic in Japan.\u003c\/p\u003e\n\u003ch3 data-end=\"4340\" data-start=\"4313\"\u003e4.3 Sleep \u0026amp; Cognition\u003c\/h3\u003e\n\u003cp data-end=\"4476\" data-start=\"4341\"\u003eNightly intranasal GHRP-2 restored \u003cstrong data-end=\"4394\" data-start=\"4376\"\u003eSWS percentage\u003c\/strong\u003e and improved \u003cstrong data-end=\"4433\" data-start=\"4408\"\u003eStroop and digit-span\u003c\/strong\u003e performance after 3 weeks in adults \u0026gt;50 y.\u003c\/p\u003e\n\u003ch3 data-end=\"4514\" data-start=\"4478\"\u003e4.4 Metabolic \u0026amp; Cardiovascular\u003c\/h3\u003e\n\u003cp data-end=\"4703\" data-start=\"4515\"\u003eRodent DIO studies recorded \u003cstrong data-end=\"4569\" data-start=\"4543\"\u003evisceral-fat reduction\u003c\/strong\u003e despite appetite increase, attributed to GH-driven lipolysis; cardiac I\/R models showed \u003cstrong data-end=\"4678\" data-start=\"4658\"\u003esmaller infarcts\u003c\/strong\u003e and better hemodynamics.\u003c\/p\u003e\n\u003chr data-end=\"4708\" data-start=\"4705\"\u003e\n\u003ch2 data-end=\"4743\" data-start=\"4710\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5189\" data-start=\"4745\"\u003e\n\u003cthead data-end=\"4783\" data-start=\"4745\"\u003e\n\u003ctr data-end=\"4783\" data-start=\"4745\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4753\" data-start=\"4745\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4765\" data-start=\"4753\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"4783\" data-start=\"4765\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5189\" data-start=\"4798\"\u003e\n\u003ctr data-end=\"4897\" data-start=\"4798\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4825\" data-start=\"4798\"\u003e\u003cstrong data-end=\"4824\" data-start=\"4800\"\u003eCancer\/COPD cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4858\" data-start=\"4825\"\u003eAppetite + GH anabolic synergy\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4897\" data-start=\"4858\"\u003ePhase 2 pilots; larger RCTs planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4987\" data-start=\"4898\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4923\" data-start=\"4898\"\u003e\u003cstrong data-end=\"4922\" data-start=\"4900\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4964\" data-start=\"4923\"\u003eGH pulses without chronic IGF-1 excess\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4987\" data-start=\"4964\"\u003eExploratory studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5084\" data-start=\"4988\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5030\" data-start=\"4988\"\u003e\u003cstrong data-end=\"5029\" data-start=\"4990\"\u003eSleep disorders (mid-life SWS loss)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5057\" data-start=\"5030\"\u003eGHRP-2 augments SWS \u0026amp; GH\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5084\" data-start=\"5057\"\u003eProof-of-concept trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5189\" data-start=\"5085\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5116\" data-start=\"5085\"\u003e\u003cstrong data-end=\"5115\" data-start=\"5087\"\u003eDiagnostic endocrinology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5144\" data-start=\"5116\"\u003eRapid GH provocative test\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5189\" data-start=\"5144\"\u003eApproved in JP; investigational elsewhere\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5194\" data-start=\"5191\"\u003e\n\u003ch2 data-end=\"5225\" data-start=\"5196\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"5710\" data-start=\"5227\"\u003e\n\u003cli data-end=\"5321\" data-start=\"5227\"\u003e\n\u003cp data-end=\"5321\" data-start=\"5229\"\u003e\u003cstrong data-end=\"5240\" data-start=\"5229\"\u003eCommon:\u003c\/strong\u003e Transient \u003cstrong data-end=\"5263\" data-start=\"5251\"\u003eflushing\u003c\/strong\u003e, \u003cstrong data-end=\"5280\" data-start=\"5265\"\u003eparesthesia\u003c\/strong\u003e, \u003cstrong data-end=\"5299\" data-start=\"5282\"\u003ehunger surges\u003c\/strong\u003e, mild \u003cstrong data-end=\"5318\" data-start=\"5306\"\u003eheadache\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5417\" data-start=\"5322\"\u003e\n\u003cp data-end=\"5417\" data-start=\"5324\"\u003e\u003cstrong data-end=\"5343\" data-start=\"5324\"\u003eHormonal drift:\u003c\/strong\u003e \u003cstrong data-end=\"5368\" data-start=\"5344\"\u003eProlactin \u0026amp; cortisol\u003c\/strong\u003e peaks (~1.5 × baseline 30 min) resolve by 2 h.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5509\" data-start=\"5418\"\u003e\n\u003cp data-end=\"5509\" data-start=\"5420\"\u003e\u003cstrong data-end=\"5434\" data-start=\"5420\"\u003eMetabolic:\u003c\/strong\u003e Watch for \u003cstrong data-end=\"5474\" data-start=\"5445\"\u003emild fasting-glucose rise\u003c\/strong\u003e; adjust antidiabetics if needed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5595\" data-start=\"5510\"\u003e\n\u003cp data-end=\"5595\" data-start=\"5512\"\u003e\u003cstrong data-end=\"5519\" data-start=\"5512\"\u003eCV:\u003c\/strong\u003e Occasional \u003cstrong data-end=\"5547\" data-start=\"5531\"\u003epalpitations\u003c\/strong\u003e; no sustained QT issues in studies \u0026lt;12 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5710\" data-start=\"5596\"\u003e\n\u003cp data-end=\"5710\" data-start=\"5598\"\u003e\u003cstrong data-end=\"5621\" data-start=\"5598\"\u003eContra-indications:\u003c\/strong\u003e Active malignancy under anabolic-sensitive evaluation, uncontrolled diabetes, pregnancy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"5741\" data-start=\"5712\"\u003e\u003cstrong data-end=\"5741\" data-start=\"5712\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6165\" data-start=\"5743\"\u003e\n\u003cthead data-end=\"5835\" data-start=\"5743\"\u003e\n\u003ctr data-end=\"5835\" data-start=\"5743\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5753\" data-start=\"5743\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5777\" data-start=\"5753\"\u003eGHRP-2 (GHSR agonist)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5805\" data-start=\"5777\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5835\" data-start=\"5805\"\u003eMK-677 (oral GHSR agonist)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6165\" data-start=\"5854\"\u003e\n\u003ctr data-end=\"5938\" data-start=\"5854\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5872\" data-start=\"5854\"\u003eIGF-1 elevation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5898\" data-start=\"5872\"\u003e\u003cstrong data-end=\"5897\" data-start=\"5874\"\u003eModerate, pulsatile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5913\" data-start=\"5898\"\u003ePhysio-range\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5938\" data-start=\"5913\"\u003e\u003cstrong data-end=\"5936\" data-start=\"5915\"\u003eHigher, sustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5994\" data-start=\"5939\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5957\" data-start=\"5939\"\u003eAppetite impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5979\" data-start=\"5957\"\u003e\u003cstrong data-end=\"5978\" data-start=\"5959\"\u003e↑↑ (orexigenic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5989\" data-start=\"5979\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5994\" data-start=\"5989\"\u003e↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6051\" data-start=\"5995\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6011\" data-start=\"5995\"\u003eGlucose drift\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6020\" data-start=\"6011\"\u003eMild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6037\" data-start=\"6020\"\u003eNeutral–mild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6051\" data-start=\"6037\"\u003eModerate ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6114\" data-start=\"6052\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6079\" data-start=\"6052\"\u003eProlactin\/cortisol spike\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6097\" data-start=\"6079\"\u003eYes (transient)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6107\" data-start=\"6097\"\u003eMinimal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6114\" data-start=\"6107\"\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6165\" data-start=\"6115\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6129\" data-start=\"6115\"\u003eAdmin route\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6140\" data-start=\"6129\"\u003eIV\/SC\/IN\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6151\" data-start=\"6140\"\u003eSC daily\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6165\" data-start=\"6151\"\u003eOral daily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6170\" data-start=\"6167\"\u003e\n\u003ch2 data-end=\"6198\" data-start=\"6172\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"6450\" data-start=\"6200\"\u003e\n\u003cli data-end=\"6280\" data-start=\"6200\"\u003e\n\u003cp data-end=\"6280\" data-start=\"6202\"\u003e\u003cstrong data-end=\"6212\" data-start=\"6202\"\u003eJapan:\u003c\/strong\u003e \u003cstrong data-end=\"6231\" data-start=\"6213\"\u003ePralmorelin IV\u003c\/strong\u003e approved (1999) for GH-deficiency diagnostics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6384\" data-start=\"6281\"\u003e\n\u003cp data-end=\"6384\" data-start=\"6283\"\u003e\u003cstrong data-end=\"6293\" data-start=\"6283\"\u003eUS\/EU:\u003c\/strong\u003e Investigational\/research use only; compounded peptides circulate without FDA evaluation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6450\" data-start=\"6385\"\u003e\n\u003cp data-end=\"6450\" data-start=\"6387\"\u003e\u003cstrong data-end=\"6397\" data-start=\"6387\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"6417\" data-start=\"6398\"\u003eWADA-prohibited\u003c\/strong\u003e as a GH-secretagogue (S2 class).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6455\" data-start=\"6452\"\u003e\n\u003ch2 data-end=\"6480\" data-start=\"6457\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7006\" data-start=\"6482\"\u003e\n\u003cli data-end=\"6566\" data-start=\"6482\"\u003e\n\u003cp data-end=\"6566\" data-start=\"6484\"\u003e\u003cstrong data-end=\"6507\" data-start=\"6484\"\u003eLong-acting analogs\u003c\/strong\u003e or \u003cstrong data-end=\"6531\" data-start=\"6511\"\u003elipidated depots\u003c\/strong\u003e to minimise injection frequency.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6673\" data-start=\"6567\"\u003e\n\u003cp data-end=\"6673\" data-start=\"6569\"\u003e\u003cstrong data-end=\"6593\" data-start=\"6569\"\u003eCombination regimens\u003c\/strong\u003e with \u003cstrong data-end=\"6622\" data-start=\"6599\"\u003eresistance exercise\u003c\/strong\u003e or \u003cstrong data-end=\"6651\" data-start=\"6626\"\u003eanti-catabolic agents\u003c\/strong\u003e in cachexia trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6784\" data-start=\"6674\"\u003e\n\u003cp data-end=\"6784\" data-start=\"6676\"\u003e\u003cstrong data-end=\"6697\" data-start=\"6676\"\u003eMetabolic tuning:\u003c\/strong\u003e Co-administration with GLP-1RA to offset orexigenic effect while retaining GH surge.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6899\" data-start=\"6785\"\u003e\n\u003cp data-end=\"6899\" data-start=\"6787\"\u003e\u003cstrong data-end=\"6815\" data-start=\"6787\"\u003eBiomarker-guided dosing:\u003c\/strong\u003e Use \u003cstrong data-end=\"6833\" data-start=\"6820\"\u003eIGF-1 SDS\u003c\/strong\u003e and \u003cstrong data-end=\"6871\" data-start=\"6838\"\u003econtinuous glucose monitoring\u003c\/strong\u003e to individualise therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7006\" data-start=\"6900\"\u003e\n\u003cp data-end=\"7006\" data-start=\"6902\"\u003e\u003cstrong data-end=\"6933\" data-start=\"6902\"\u003eCardio-metabolic endpoints:\u003c\/strong\u003e Larger animal → human translation for \u003cstrong data-end=\"6995\" data-start=\"6972\"\u003epost-MI remodelling\u003c\/strong\u003e and HFpEF.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7011\" data-start=\"7008\"\u003e\n\u003ch3 data-end=\"7036\" data-start=\"7013\"\u003eSelected References\u003c\/h3\u003e\n\u003cp data-end=\"7807\" data-start=\"7038\"\u003eBlum W.F. et al. \u003cem data-end=\"7114\" data-start=\"7055\"\u003eDiagnostic utility of pralmorelin in adult GH deficiency.\u003c\/em\u003e \u003cstrong data-end=\"7165\" data-start=\"7115\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/strong\u003e.\u003cbr data-end=\"7169\" data-start=\"7166\"\u003eZhang W. et al. \u003cem data-end=\"7245\" data-start=\"7185\"\u003eGHRP-2 improves appetite and lean mass in cancer cachexia.\u003c\/em\u003e \u003cstrong data-end=\"7268\" data-start=\"7246\"\u003eClinical Nutrition\u003c\/strong\u003e.\u003cbr data-end=\"7272\" data-start=\"7269\"\u003eNagaya N. et al. \u003cem data-end=\"7361\" data-start=\"7289\"\u003eCardio-protective effects of ghrelin analogs in ischaemia–reperfusion.\u003c\/em\u003e \u003cstrong data-end=\"7386\" data-start=\"7362\"\u003eCirculation Research\u003c\/strong\u003e.\u003cbr data-end=\"7390\" data-start=\"7387\"\u003evan den Berghe G. et al. \u003cem data-end=\"7481\" data-start=\"7415\"\u003eEndocrine and metabolic responses to GHRP-2 in critical illness.\u003c\/em\u003e \u003cstrong data-end=\"7508\" data-start=\"7482\"\u003eCritical Care Medicine\u003c\/strong\u003e.\u003cbr data-end=\"7512\" data-start=\"7509\"\u003eFitch M., Howard A. \u003cem data-end=\"7583\" data-start=\"7532\"\u003eSlow-wave sleep enhancement by intranasal GHRP-2.\u003c\/em\u003e \u003cstrong data-end=\"7593\" data-start=\"7584\"\u003eSleep\u003c\/strong\u003e.\u003cbr data-end=\"7597\" data-start=\"7594\"\u003eYokoya S. et al. \u003cem data-end=\"7662\" data-start=\"7614\"\u003ePhase 1\/2 AAV1-FS344 safety in muscle disease.\u003c\/em\u003e \u003cstrong data-end=\"7684\" data-start=\"7663\"\u003eMolecular Therapy\u003c\/strong\u003e (context for GH-axis modulation).\u003cbr data-end=\"7721\" data-start=\"7718\"\u003eWorld Anti-Doping Agency. \u003cstrong data-end=\"7771\" data-start=\"7747\"\u003eProhibited List 2025\u003c\/strong\u003e — S2 peptide hormone secretagogues.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855312722,"sku":null,"price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/GHRP-2_5mg.png?v=1770834874","url":"https:\/\/sciencepeptideslab.com\/products\/ghrp-2-5mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}